UNSPSC 51342805: Delavirdine mesilate or mesylate

This classification denotes a reverse transcriptase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 421105KRQE. European Medicines Agency schedules Delavirdine mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01575MIG. Delavirdine mesylate generally arises in the molecular formula C22H28N6O3S.CH4O3S. The term 'delavirdine mesylate' is a Japanese Accepted Name designation. Most nations, for tariff and trade purposes, schedule delavirdine mesylate under HS 29350090 and SITC 51580.

As of Q4 2014, DELAVIRDINE MESYLATE remains US FDA's Preferred Term for this commodity. Delavirdine mesylate bears US NLM identifiers UMLS ID C0543492 and NCI Concept Code C28974. SMILES: CC(C)NC1CCCNC1N2CCN(CC2)C(=O)C3CC4CC(CCC4[NH]3)NS(=O)(=O)C.CS(=O)(=O)O.

UNSPSC 51342805 Delavirdine mesilate or mesylate, a Commodity code, shows minimal alignment between its nominal scope and recent state and local procurement activity. The code's pharmaceutical specificity—a single antiretroviral agent—does not match the breadth of work actually being solicited under this code number. Recent opportunities tagged with 51342805 span naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products via cooperative purchasing, direct-to-manufacturer prescription programs, and emergency medical supplies. State and local buyers posting under this code include single jurisdictions (Seminole County, Florida and the City of Tampa), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across participating jurisdictions including Oregon). The mismatch suggests either inconsistent code assignment within procurement systems or broader pharmaceutical commodity groupings than the code title indicates.

Activity appears concentrated in the Southeast and Midwest. Recent solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries (response deadline July 26, 2023); the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division with an estimated contract value of $700,000.00 and a sheltered market set-aside for certified Small Local Business Enterprises (response deadline March 13, 2026); the Texas Health and Human Services Commission's RFI regarding Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions (response deadline April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC (response deadline March 26, 2026). This code shows limited decision value for vendors focused on antiretroviral pharmaceutical supply; the recent posting pattern reflects broad emergency medical and pharmacy commodity procurement rather than HIV treatment agents.